• Innovation by DNA.

Faster, simpler and better molecular detection.

Check-Points is a pioneer in innovative DNA testing methods in the industry and health sector since its foundation in 2002. Deoxyribonucleic acid, short for DNA, is a molecule that carries the genetic instructions used in the growth, development, functioning and reproduction of all known living organisms and many viruses.

Check-Points has used the specific characteristics of DNA to develop a range of rapid molecular assays which support commercial organizations and hospitals in identifying and serotyping of Salmonella using molecular diagnostics. Check-Points has also developed molecular assays to detect beta-lactam resistance in the form of carbapenemases, ESBLs and AmpCs within Enterobacteriaceae.

Check-Points’ innovation by DNA helps to fight serious health problems like Salmonella and multi-drug resistance (MDR).

“We focus on the development and commercialization of a new generation of molecular diagnostic solutions.”

Check-Direct & Check-MDR

With our range of products for detection of carbapenemases, ESBLs and AmpCs we aim to improve the control and prevention of antibiotic resistance in Gram-negative bacteria through combining our unique know-how of this field with our molecular detection technologies.

Our CE-IVD marked products range from a proprietary microarray system for comprehensive identification of resistance genes to assays for rapid screening in as fast as 2 hours based on real-time PCR.

Check & Trace Salmonella

Check & Trace Salmonella (previously Premi®Test Salmonella) is the first product in our Check & Trace range for food and veterinary diagnostics.

Check & Trace Salmonella allows for fast and reliable routine molecular confirmation and serotyping of Salmonella. Serotyping of Salmonella has proven to be essential in any Salmonella reduction program.

Read more on www.checkandtrace.com >>

Contact

Check-Points Health
Binnenhaven 5
6709 PD Wageningen
The Netherlands

+31 (0) 317 453 908
info@check-points.com

Subscribe to our newsletter?